Findings

What do systematic reviews say?

7 questions · 9 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 9 · 100%

Disease-free survival · neoadjuvant therapy for early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).

2 findings from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.63 [0.53, 0.75]
8 studies · 1966 participants
High
Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.63 [0.53, 0.75]
8 studies · 1966 participants
High

OS at 2 years · neoadjuvant therapy for early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.69 [0.55, 0.86]
8 studies · 1973 participants
High

OS at 5 years · neoadjuvant therapy for early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.69 [0.55, 0.86]
8 studies · 1973 participants
High

Pathological complete response · neoadjuvant therapy for early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to higher pathological complete response compared with chemotherapy without platinum (high certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
RR 1.44 [1.31, 1.59]
15 studies · 3083 participants
High

Disease-free survival · early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).

2 findings from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.69 [0.54, 0.88]
4 studies · 1256 participants
High
Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.69 [0.54, 0.88]
4 studies · 1256 participants
High

OS at 2 years · early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.7 [0.5, 0.96]
4 studies · 1256 participants
High

OS at 5 years · early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.7 [0.5, 0.96]
4 studies · 1256 participants
High